OTC Markets · Biotechnology · USD

Aditxt, Inc. (ADTX) Stock Analysis

Aditxt, Inc. (ADTX) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.

ADTX

$0.01

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADTX with… →

ADTX Key Statistics

As of Sep 4, 2026

Trading

Open: $0.01
Previous Close: $0.01
52-Week Range: 0.00–27,092.88
Volume: 10.07M

Valuation

Market Cap: $6.99M
P/S ratio: 487.29

Financials (FY)

Revenue (FY): $3.20K−97.62%
Net Income (FY): −$41.71M
Profit margin: 0.00%
Shares Outstanding: 997.98M
1-Year Return: −99.99%

Dividend and dates

Avg Volume: 423.83M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ADTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−99.16%
2025	−99.98%

As of September 4, 2026.

ADTX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$3.20K	−$41.71M	−1305608.8%
2024	$133.99K	−$34.45M	−25709.2%
2023	$645.18K	−$32.38M	−5018.9%
2022	$933.72K	−$27.65M	−2961.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$3.20K	$268.00	−$19.57M	−$41.71M	−1305608.8%
2024	$133.99K	−$493.49K	−$27.86M	−$34.45M	−25709.2%
2023	$645.18K	−$111.66K	−$26.06M	−$32.38M	−5018.9%
2022	$933.72K	$166.94K	−$24.94M	−$27.65M	−2961.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADTX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	ADTX	Biotechnology median	vs median
P/S ratio	487.29	15.26	31.9x the median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Aditxt, Inc. (ADTX) is capitalised at $6.99M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 26 employees.

The most recent close on file for ADTX is $0.01, dated September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $0.00 to $27,092.88. The latest close sits 250% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.20K. That is −97.62% against the prior fiscal year, when revenue was $133.99K. The same year closed with a net loss of $41.71M. The reported profit margin is 0%.

Across the 4 fiscal years on file, revenue moves from $933.72K in 2022 to $3.20K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The price-to-sales ratio is 487.29. On price-to-sales that is 31.9 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Annualized volatility over the trailing 1 year is 2,587.17%. The trailing one-year price return is −99.99%. The stored price history starts on January 10, 2025, and the total return since then is −100.00%.

Growth & Income

The record shows no dividend for ADTX.

The record holds one complete calendar year, 2025, which returned −99.98%. 2026 is still running; the price is −99.16% year to date.

Peer Comparison

Aditxt, Inc. (ADTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Aditxt, Inc.	ADTX	$6.99M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Aditxt, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Aditxt, Inc.

Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Visit website →